loading...| Preferred Name |
arsenic trioxide |
|
| Synonyms |
Arsenic (III) Oxide |
|
| Definitions |
A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1005" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1005" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000043067 |
|
| altLabel |
Arsenic (III) Oxide Arsenous Oxide White Arsenic Arsenous Acid Anhydride Arsenous Acid Arsenic Sesquioxide Trisenox AS2O3 |
|
| CAS Registry |
1327-53-3 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000430890 http://purl.bioontology.org/ontology/PDQ/CDR0000405822 http://purl.bioontology.org/ontology/PDQ/CDR0000436860 http://purl.bioontology.org/ontology/PDQ/CDR0000420969 http://purl.bioontology.org/ontology/PDQ/CDR0000390236 http://purl.bioontology.org/ontology/PDQ/CDR0000269719 http://purl.bioontology.org/ontology/PDQ/CDR0000038012 http://purl.bioontology.org/ontology/PDQ/CDR0000371824 http://purl.bioontology.org/ontology/PDQ/CDR0000430891 http://purl.bioontology.org/ontology/PDQ/CDR0000440123 http://purl.bioontology.org/ontology/PDQ/CDR0000426494 http://purl.bioontology.org/ontology/PDQ/CDR0000383247 |
|
| cui |
C4316929 C1096917 C0052422 C0052416 |
|
| Date last modified |
2006-05-08 |
|
| definition |
A small-molecule arsenic compound with antineoplastic activity. The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1005" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1005" NCI Thesaurus) |
|
| IND Code |
57974 |
|
| Legacy PDQ ID |
7430 |
|
| LT |
TRD |
|
| NCI ID |
C1005 |
|
| notation |
CDR0000043067 |
|
| NSC Code |
706363 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
arsenic trioxide |
|
| tui |
T197 T131 T121 |